
    
      This is a prospective multicentre, randomised, open label, study comparing the efficacy and
      the safety of six 3-weekly cycles cabazitaxel versus 18 x weekly paclitaxel given as first
      line chemotherapy treatment in patients with HER2-normal metastatic breast cancer.
      Randomisation will be conducted by a 1:1 ratio.
    
  